Abstract: Multinuclear complexes and methods for preparing them are provided. The discrete multinuclear complexes include a one or more transition metals and a radioisotope having the same coordination geometry as the transition metal. A bridging ligand is coordinated to the transition metal and the radioisotope to link the transition metal and the radioisotope and pendent ligands are coordinated to each of the transition metal and the radioisotope to stabilise the complex. The multinuclear complexes may include a radioisotope or radioelement that can be detected by medical equipment and may find use in therapy and/or the diagnosis of disease in patients.

Abstract: The present invention concerns a tissue-engineered medical device, as well as a method for the production said medical device, comprising the following steps: providing a polymer scaffold comprising a mesh comprising polyglycolic acid, and a coating comprising poly-4-hydroxybutyrate; application of a cell suspension containing preferably human cells to the polymer scaffold; placement of the seeded polymer scaffold in a bioreactor and mechanical stimulation by exposure to a pulsatile flux of incremental intensity, thereby forming an extracellular matrix; mounting of the graft on a conduit stabilizer and incubation in cell culture medium; decellularisation of the graft in a washing solution; nuclease treatment of the graft; and rinsing of graft. The invention further comprises and various steps of quality control of the tissue-engineered medical device.

Abstract: The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.

Abstract: The invention relates to a method for selecting a sequence set from a library of expressed nucleic acid sequences, wherein cells are provided, each cell comprises an expressed nucleic acid sequence expressed as a target protein. The cells are encapsulated by treating them with a cationic polysaccharide and subsequently treating them with an anionic polysaccharide, yielding encapsulated cells, perforating the membrane of the encapsulated cells, yielding solubilized compartments, contacting them with a ligand to said target protein, the ligand bearing a detectable label, and selecting a subset of solubilized compartments as a function of detectable label and isolating the expressed nucleic acid sequences from the selection as a selected sequence set.

Abstract: Described herein is the use of a non-agonist ligand, particularly an antibody, specifically binding to GM-CSF or one of CD116, CD131 and the GM-CSF receptor composed of CD116 and CD131 for use in treatment of leukemia in a patient having undergone allo-HCT or in treatment of other complications arising as a consequence of hematopoietic cell transplantation from an immunologically non-identical donor.

Abstract: The present invention relates to a non-agonist ligand of ARTC1, which inhibits the ADP-ribosyltransferase activity of ARTC1, or an inhibitor nucleic acid sequence capable of downregulating or inhibiting expression of a target nucleic acid sequence encoding ARTC1, for use in prevention or treatment of cancer. The invention also relates to a method for diagnosis of cancer.

Abstract: A delivery system (10, 110) is provided for delivering and deploying an implantable balloon-based occlusion device (20) including an inflatable balloon (22). The delivery system (10, 110) includes a delivery handle (11), which includes a fluid-retaining chamber (41, 141); a plunger, which is slidingly disposed in the fluid-retaining chamber (41, 141); and a proximal rotatable user-control knob (31). A fluid-conveyance lumen catheter (18) defines a catheter fluid-conveyance lumen (19) in fluid communication with the fluid-retaining chamber (41, 141) and the inflatable balloon (22). A catheter lumen shaft (26) is in reversible connection with the balloon-based occlusion device (20), longitudinally slidable with respect to the delivery handle (11).

Abstract: The present invention relates to an immersion microscope objective (10) for inspecting a sample (S) in an immersion medium (M), comprising: at least one concave minor (3), at least one optical element (1) comprising an aspherical surface (2) facing the at least one concave minor (3), and an internal space (4) arranged between the at least one concave minor (3) and said aspherical surface (2), said internal space (4) being configured to be filled with an immersion medium (M) such that the immersion medium (M) contacts the at least one concave minor (3) and the aspherical surface (2). According to the present invention, the aspherical interface (2) is shaped such that the working distance (7) of the immersion microscope objective (10) varies by less than 1% when the refractive index n of said immersion medium (M) is increased or decreased by at least 0.025.

Abstract: A modular artificial neural sensing system includes a hierarchical network of neural sensing units including a neuromimetic sensor array of artificial sensory synapses and sensory neurons for receiving physicochemical sensed signals and for outputting sensor output signals. An artificial neural network processor is adapted for processing the sensor output signals and includes processor neurons interconnected by processor synapses forming first connections and second connections. The processor outputs processor output signals. A first sensor interface feeds processed or unprocessed sensed signals into the processor. A second sensor interface receives output predicted signals from other neural sensing units and feeds processed or unprocessed output predicted signals into the processor. A signal decoder decodes the processor output signals and outputs decoder output signals.

Abstract: A computer-implemented method is used to adapt a first artificial neural network for data classification tasks. The first artificial neural network is characterized by a first number of first weight parameters, and includes a set of first network layers. The method includes freezing at least some of the first weight parameters of the first neural network to obtain frozen first weight parameters and duplicating the frozen first weight parameters to obtain duplicated first weight parameters. A second artificial neural network is applied to the duplicated first weight parameters to obtain modulated first weight parameters. The second artificial neural network is characterized by a second number of second weight parameters, the second number being smaller than the first number. The frozen first weight parameters are replaced in the first neural network with the modulated first weight parameters to obtain a modulated first artificial neural network adapted for a data classification task.

Abstract: The invention provides a bacterial composition comprising, or consisting of, one or more of the genera of bacteria selected from Anaerostipes, and/or Roseburia, for treatment, or for prevention of recurrence, of cancer. In another aspect, the invention relates to a combination medicament for use in the treatment or the prevention of recurrence of cancer comprising a bacterial composition as specified herein and an antineoplastic treatment, particularly a combination medicament comprising a bacterial composition and a cancer chemotherapy drug, or a bacterial composition as provided herein and a cancer immunotherapy drug.

Abstract: The invention is related to a device (1) for receiving a biological sample (3) wherein the device (1) comprises a plurality of wells (10) wherein each well (10) comprises an inner surface (14) facing a volume (60) for receiving a biological sample (3). The inner surface (14) comprises a top section (20) and a bottom section (30). The top section (20) and the bottom section (30) are connected via a circumferential step (40). The circumferential step (40) forms a stop for a tip of a pipette (70).

Abstract: The present invention relates to the use of a composition in a method of reducing the allergenicity of a cat. Moreover, the present invention relates to the use of a composition in a method of reducing the allergenicity of a cat for a human exposed to the cat. Furthermore, the present invention relates to compositions comprising a virus-like particle (VLP) and at least one Fel d1 protein. The compositions of the invention induce efficient immune responses, in particular antibody responses, in cats and are useful for the treatment and/or prevention of cat allergy.

Abstract: The invention relates to a method to indicate the clinical outcome of a cancer patient by labelling a cancer sample with labelled molecular probes, assaying the expression of a plurality of biomolecules at the resolution of a single cell and assigning a cellular identity (CI) to each single cell in the sample based on their expression pattern; then assigning a single cell pathology (SCP) patient group according to the proportion of each CI the sample contains. The invention in other aspects relates to methods of treatment of a patient with anticancer drugs according to the patient's assignment to particular SCPs. Alternatively, this aspect may be formulated as the provision of certain drugs for treatment of cancer in patients characterized by tumours assigned to certain SCPs.

Abstract: A compound for use in the treatment of itch is provided, wherein the compound comprises the general formula (1a), general formula (1b) or general formula (1c). The compounds of the invention are positive allosteric ?2 and/or ?3 GABAA receptor modulators.

Abstract: An occluder device is provided for occluding a cardiovascular defect or a gap between a medical device and adjacent body tissue, the device including a compliant balloon defining a fluid-tight balloon chamber and a balloon channel forming a longitudinal passage from a proximal to a distal side of the balloon, the balloon including a fluid port for filling a fluid into the balloon chamber. A tip and a base are coupled to the distal and the proximal sides of the balloon, respectively. At least one connecting strut is attached to the tip and to the base. An elongate actuator is disposed longitudinally slidable in the balloon channel and connected to the tip, and longitudinally slidable with respect to the base so as to set a distance between the tip and the base. A lock is configured to maintain the distance between the tip and the base. Other embodiments are also described.

Abstract: An occlusion device (210) is provided for occluding a left atrial appendage (LAA), including a compliant balloon (230) defining a fluid-tight balloon chamber (232), and an actuating shaft (234), which is disposed at least partially within the balloon chamber (232) for setting a distance between distal and proximal end portions (236, 238) of the balloon (230). A proximal LAA-orifice cover (70) includes a frame (72) and a covering (74) fixed to the frame (72). An orifice-support stent (290) is fixed to and extends distally from the proximal LAA-orifice cover (70), and is generally cylindrical when in a radially-expanded state. Other embodiments are also described.

Abstract: The invention relates to derivatives of apramycin-based aminoglycoside antibacterial drugs modified in positions C5 and/or C6 and O5 and/or O6. The modifications impart favourable properties regarding increased selectivity and retention of activity in the presence of resistance determinants of the AAC(3) class. The invention further relates to said compounds for use in the therapy of bacterial infection by systemic administration, especially in instances where the infection is caused by a pathogen comprising a resistance determinant of the AAC(3) class, in particular AAC(3)-IV.

Abstract: The invention relates to a HLA-B27 Fc open conformer or a HLA-B27 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B27 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B27 Fc open conformer and immune checkpoint inhibitors.

Abstract: An occluder device is provided for occluding a cardiovascular defect or a gap between a medical device and adjacent body tissue, the device including a compliant balloon defining a fluid-tight balloon chamber and a balloon channel forming a longitudinal passage from a proximal to a distal side of the balloon, the balloon including a fluid port for filling a fluid into the balloon chamber. A tip and a base are coupled to the distal and the proximal sides of the balloon, respectively. At least one connecting strut is attached to the tip and to the base. An elongate actuator is disposed longitudinally slidable in the balloon channel and connected to the tip, and longitudinally slidable with respect to the base so as to set a distance between the tip and the base. A lock is configured to maintain the distance between the tip and the base. Other embodiments are also described.